Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer
SEOUL, South Korea — Maintenance therapy with selinexor (Xpovio) seemed to substantially extend progression-free survival (PFS) in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to data from the SIENDO trial. The updated, long-term data from the phase III study showed that, at a median follow-up of 25.3 months, median PFS was 27.4 […]